Table 4.
Univariate analyses of disease-free survival and overall survival
| Variables | Category | Disease-free survival | Overall survival | ||
|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | ||
| Age | < 50 yrs vs. ≥50 yrs | 0.775 (0.335–1.792) | 0.552 | 0.964 (0.359–2.588) | 0.941 |
| Histologic type | IC-NST vs. othersa | 1.609 (0.478–5.416) | 0.443 | 0.697 (0.092–5.281) | 0.727 |
| T stage | T1-2 vs. T3-4 | 3.386 (1.003–11.436) | 0.049 | 1.513 (0.199–11.500) | 0.689 |
| N stage | N0 vs. N1-3 | 1.935 (0.837–4.473) | 0.123 | 1.759 (0.639–4.843) | 0.274 |
| LVI | Absent vs. Present | 3.643 (1.544–8.595) | 0.003 | 3.054 (1.109–8.407) | 0.031 |
| Histologic grade | II vs. III | 1.015 (0.238–4.329) | 0.984 | 1.494 (0.197–11.316) | 0.697 |
| DCIS | Absent vs. Present | 3.005 (0.892–10.120) | 0.076 | 1.395 (0.449–4.338) | 0.565 |
| Tumor border | Pushing vs. Infiltrative | 0.885 (0.375–2.089) | 0.781 | 1.740 (0.652–4.645) | 0.269 |
| Multicentricity | Absent vs. Present | 1.482 (0.550–3.993) | 0.437 | 1.718 (0.554–5.328) | 0.349 |
| TIL | < 10% vs. ≥10% | 0.387 (0.171–0.878) | 0.023 | 0.693 (0.252–1.911) | 0.479 |
| CD4+ TIL | Low vs. High | 0.258 (0.096–0.696) | 0.007 | 0.439 (0.152–1.263) | 0.127 |
| CD8+ TIL | Low vs. High | 0.266 (0.099–0.716) | 0.009 | 0.587 (0.213–1.617) | 0.303 |
| CD56+ TIL | Low vs. High | 0.328 (0.129–0.833) | 0.019 | 0.578 (0.210–1.592) | 0.289 |
| CD57+ TIL | Low vs. High | 0.416 (0.171–1.012) | 0.053 | 0.593 (0.215–1.631) | 0.311 |
| GNLY+ TIL | Low vs. High | 0.401 (0.165–0.976) | 0.044 | 0.563 (0.204–1.551) | 0.266 |
| GZMB+ TIL | Low vs. High | 0.621 (0.269–1.436) | 0.266 | 0.985 (0.370–2.625) | 0.976 |
| CTL-NK score | 0–1 vs. 2–5 | 0.357 (0.154–0.825) | 0.016 | 0.451 (0.168–1.212) | 0.114 |
p values were calculated by Cox proportional hazards model
aInclude metaplastic carcinoma and carcinoma with apocrine differentiation
HR, hazard ratio; CI, confidence interval; Yrs, years; IC-NST, invasive carcinoma of no special type; LVI, lymphovascular invasion; DCIS, ductal carcinoma in situ; TIL, tumor-infiltrating lymphocyte; DCIS, ductal carcinoma in situ; GNLY, granulysin; GZMB, granzyme B; CTL, cytotoxic T lymphocyte; NK, natural killer